{"id":3697,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/argatroban-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"argatroban-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/argatroban-txt\/","title":{"rendered":"Argatroban.txt"},"content":{"rendered":"

Argatroban<\/h1>\n

CLINICAL USE <\/H3>
\nAnticoagulant:<\/p>\n
  • Prophylaxis or treatment of thrombosis\n

    in patients with heparin-induced
    \nthrombocytopenia (HIT)<\/p>\n

  • Adjunct in patients at risk of HIT\n

    undergoing percutaneous coronary
    \nintervention
    \n

    DOSE IN NORMAL RENAL FUNCTION <\/H3><\/p>\n
  • Anticoagulant for prophylaxis or\n

    treatment of thrombosis: infusion of
    \n2 mcg\/kg\/min; adjust according to
    \nresponse (APTT); maximum
    \n10 mcg\/kg\/min<\/p>\n

  • Anticoagulant for patients undergoing\n

    percutaneous coronary intervention:
    \ninitially a bolus of 350 mcg\/kg
    \nadministered via a large bore IV line over
    \n3\u20135 minutes, followed by an infusion of
    \n25 mcg\/kg\/min. Additional IV bolus doses
    \nof 150 mcg\/kg may be given if required and
    \nthe infusion rate changed to
    \n15\u201340 mcg\/kg\/min
    \n

    PHARMACOKINETICS <\/H3>
    \n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n508.6\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n54\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n16\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n0.17\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n39\u201351 minutes\/
    \nUnchanged
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
    \n
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nDose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nNot dialysed. Dose as in normal renal function
    \n
  • HDF\/high flux &nbsp :
    \nNot dialysed. Dose as in normal renal function
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Heparin: avoid concomitant\n

    administration<\/p>\n

  • Urokinase: may increase the risk of\n

    bleeding<\/p>\n

  • Thrombolytics: may increase risk of\n

    bleeding complications; enhance effect of
    \nargatroban<\/p>\n

  • Antiplatelets and anticoagulants: increased\n

    risk of bleeding complications
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nIV<\/p>\n

    Rate of Administration <\/H4>
    \nBolus: over 3\u20135 minutes<\/p>\n

    Infusion: 2\u201325 mcg\/kg\/min<\/p>\n

    Comments<\/H4><\/p>\n
  • Physically and chemically stable for up to\n

    96 hours if refrigerated or at controlled
    \nroom temperature and protected from
    \nlight<\/p>\n

  • Dilute to 1 mg\/mL with sodium chloride\n

    0.9%, glucose 5% or Lactated Ringer\u2019s
    \nsolution, i.e. 250 mg (2.5 mL) into 250 mL
    \nof diluent. The solution must be mixed by
    \ninversion for 1 minute
    \n

    OTHER INFORMATION <\/H4><\/p>\n
  • Can also be used for haemodialysis\n

    anticoagulation: 0.1 mg\/kg bolus, followed
    \nby a continuous infusion of 0.1-0.2 mg\/kg\/
    \nhour, dosing being adjusted to maintain an
    \nAPTT 1.5\u20133 times normal. <\/p>\n

  • For CVVHD a dose of 0.5\u20131 mcg\/kg\/min\n

    was suggested, dosing being adjusted to
    \nmaintain an APTT 1.5\u20132 times normal. <\/p>\n

  • 20% of argatroban is removed during a\n

    4 hour dialysis session<\/p>\n

  • There is no specific antidote\n
  • Contraindicated in patients with overt\n

    major bleeding<\/p>\n","protected":false},"excerpt":{"rendered":"

    Argatroban CLINICAL USE Anticoagulant: Prophylaxis or treatment of thrombosis in<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3697","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3697"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3697\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}